Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2020 | Latest updates in myeloma: key takeaways from ASH 2020

Daniel Auclair • 15 Dec 2020
ASH 2020
Multiple Myeloma Rare Diseases Smoldering Myeloma BiTEs

Daniel AuClair, PhD, Multiple Myeloma Research Foundation, Norwalk, CT, discusses recent advances in multiple myeloma research that were presented at ASH 2020. These include progression in the bispecific antibody field, with new targets beyond BCMA being investigated. For example, data on GPRC5D-directed bispecifics was shown, as well as novel combinations of immune and targeted therapies. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

More from Daniel Auclair

2:50
IMW 2021: MRD highlights
Daniel Auclair • 11 Sep 2021
5:24
Novel immunotherapies for multiple myeloma
Daniel Auclair • 8 Apr 2021
5:59
myDRUG: precision medicine in multiple myeloma
Daniel Auclair • 8 Apr 2021
5:58
What’s to come for the MMRF in 2021?
Daniel Auclair • 15 Dec 2020

Related Videos

4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:18
Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals